Advertisement
Screener

ACRO BIOMEDICAL CO., LTD. (ACBM) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

ACRO BIOMEDICAL CO., LTD. Increase (Decrease) in Deferred Revenue

ACRO BIOMEDICAL CO., LTD. (ACBM) reported Increase (Decrease) in Deferred Revenue of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-15.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-04-15

  • ACRO BIOMEDICAL CO., LTD. increase (decrease) in deferred revenue for the quarter ending 2021-12-31 was $0.00.
  • ACRO BIOMEDICAL CO., LTD. increase (decrease) in deferred revenue for the quarter ending 2021-09-30 was $0.00.
  • ACRO BIOMEDICAL CO., LTD. increase (decrease) in deferred revenue for the quarter ending 2020-12-31 was $0.00.
  • ACRO BIOMEDICAL CO., LTD. increase (decrease) in deferred revenue for the quarter ending 2020-09-30 was $0.00.
  • ACRO BIOMEDICAL CO., LTD. increase (decrease) in deferred revenue for fiscal 2021 was $0.00.
  • ACRO BIOMEDICAL CO., LTD. increase (decrease) in deferred revenue for fiscal 2020 was -$17.46K.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15
$0.00
derived: sum of 2 quarters · filed 2022-04-15
$0.00
10-K · filed 2022-04-15
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22
$0.00
10-Q · filed 2021-11-22
2021-06-30$0.00
10-Q · filed 2021-08-23
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15
$0.00
derived: sum of 2 quarters · filed 2022-04-15
-$17.46K
10-K · filed 2022-04-15
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22
-$17.46K
10-Q · filed 2021-11-22
2020-06-30-$17.46K
10-Q · filed 2021-08-23
2018-03-31-$163.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
$64.82K
10-Q · filed 2018-08-01
2017-12-31$64.98K
10-Q · filed 2018-02-14